August J. Moretti
Independent DirectorMr. August J. Moretti, Esq., JD, also known as Augie, serves as Independent Director at Cibus Inc. since 2025. He is Independent Director of Vivani Medical, Inc. from June 24, 2026. He was Chief Financial Officer at 4D Molecular Therapeutics, Inc. since January 2019 until September 2023. He serves as Independent Director at Cibus, Inc. (Formerly known as Calyxt, Inc.) since November 18, 2024. He serves as Independent Director at Pixium Vision SA since June 22, 2022. he was the CFO of Assertio Therapeutics from 2012 to 2018 and held CFO and General Counsel roles at Alexza Pharmaceuticals, Inc., which was publicly held until its acquisition by Ferrer Pharmaceuticals and Alavita, Inc. Earlier in his career, Mr. Moretti was a partner at Heller Erhman, where he represented life science companies in mergers, acquisitions and public financings. He serves as a member of the Board and chair of the Audit Committee for Cibus, Inc. He serves as Director of Neumentum, Inc. since April 2019. Mr. Moretti started employment with 4D Molecular Thera peutics on January 7, 2019. He was the Chief Financial Officer and Senior Vice President at Assertio Therapeutics (formerly Depomed, Inc.) since January 3, 2012 until August 2018 and served as its Principal Accounting Officer. Mr. Moretti served as the Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals Inc. (formerly, Alexza Molecular Delivery Corp.) from 2004 to December 31, 2011 and served as its General Counsel from October 2010 to December 31, 2011. Mr. Moretti served as Secretary of Alexza Pharmaceuticals Inc. from December 2005 to December 31, 2011 and served as its Principal Accounting Officer until May 2010. He served as Chief Financial Officer and General Counsel of Alavita, Inc. (formerly PPD Biomarker Discovery Sciences LLC and Surromed Inc.) from January 2001 to January 2004. He served at Heller Ehrman LLP. Mr. Moretti is an experienced senior financial executive and expert in securities law whose involvement in the biopharmaceutical industry spans more than three decades. Mr. Moretti has extensive experience with both private and public companies on issues relating to disclosure and public reporting and public and private financings (notably working on IPO / public financings for Cetus, Affymax, Affymetrix, Maxygen, Cepheid, Thoratec, Inhale, Isis and Catalytica). He serves as a Member of Advisory Board of Taraval Associates LLC. He was a Advisor at Taraval Associates Seed Capital Fund L.P. He served as a Member of Heller Ehrman White & McAuliffe LLP, where he represented a number of life science companies, including Affymax and Maxygen from January 1982 to December 2000. From 1982 to 2000 Mr. Moretti was a Partner in an international law firm. Mr. Moretti holds a B.A degree in Economics from Princeton University in 1972 and a J.D from Harvard Law School in 1975.
Positions
- Company NameCibus, Inc.Stock CodeCBUSPositionIndependent DirectorColleagues
- CWCraig WichnerChief Executive Officer
- MTMark Terrence FinnIndependent Chairman
- PRPeter R. BeethamCo-Founder, President & COO
- GFGregory F. GocalCo-Founder, Chief Scientific Officer & Executive VP
- RBRory Balfour RiggsCo-Founder & Director
- JSJason StokesChief Administrative Officer, General Counsel & Corporate Secretary
- GPGerhard PranteIndependent Director
- JLJean-Pierre LehmannIndependent Director
- Company NameVivani Medical, Inc.Stock CodeVANIPositionIndependent DirectorColleagues
- AMAdam MendelsohnCo-Founder, CEO & Director
- GGGregg G. WilliamsIndependent Chairman of the Board
- AEAnthony Edward BaldorChief Financial Officer
- TLTruc LeChief Operations Officer
- LELisa E. PorterChief Medical Officer
- DDDonald DwyerChief Business Officer & Corporate Secretary
- DMDaniel Mark BradburyIndependent Director
- AJAugust J. MorettiIndependent Director
- AMAaron MendelsohnDirector
